VivoSeq
Infectious Disease

Long COVID-19

23

Pipeline Programs↗

7

Active Trials↗

15

Companies Involved↗

Long COVID-19 is an emerging landscape with 23 programs across 15 companies. The most active players are Pfizer, Eli Lilly, EMD Serono. 9 therapies are approved with 6 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

50/100

Pipeline Velocity

11/100

Mech. Concentration

7/100

Completion Rate

50/100

Attrition Rate

22/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

2 programs

Phase 2Eli Lilly logo

Eli Lilly

1 program

Phase 3EMD Serono logo

EMD Serono

1 program

Phase 3GSK logo

GSK

1 program

Phase 3G

Glaxo Dba Glaxosmithkline

1 program

ApprovedM

Milestone Pharmaceuticals Inc.

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

89%

Small molecule

25 of 28 classified programs — the dominant modality here.

11%ALL OTHERSCell therapy27%Vaccine14%

Small molecule leads; the ring shows all 28 classified programs, each share of the total. Modality classified for 100% of 30 pipeline programs.

Analysis

Trial Status

18

clinical trials

Withdrawn4 · 22%
Completed4 · 22%
Active, not recruiting3 · 17%
Unknown status3 · 17%
Recruiting2 · 11%
Not yet recruiting2 · 11%

Clinical Trials

Trial Activity

18 trials

Antiviral Clinical Trial for Long Covid-19
Recruiting·IIcahn School of Medicine at Mount Sinai·Phase 2·NCT06511063·90 enrolled
Low Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19
Recruiting·IIcahn School of Medicine at Mount Sinai·Phase 3·NCT06960928·80 enrolled
Probiotic Use for Recovery Enhancement From Long COVID-19
Active, not recruiting·RRush University Medical Center·Phase 2·NCT06643299·180 enrolled
Long COVID-19 [11C]CPPC Study
Active, not recruiting·JJohns Hopkins University·Phase 1·NCT06223971·6 enrolled
PAxlovid loNg cOvid-19 pRevention triAl With recruitMent In the Community in Norway
Active, not recruiting·HHaukeland University Hospital·Phase 3·NCT05852873·2,000 enrolled
Investigating Measurable PRO Acuity Trial (IMPACT) is a Multi-Center Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Maraviroc and Atorvastatin to Improve Neurocognitive and Physical Function of Subjects With Long COVID-19/Post-Acute Sequelae of COVID-19 (PASC).
Not yet recruiting·HHealthBio, Inc.·Phase 2/3·NCT06974084·252 enrolled
A Study to Assess Anktiva in Patients With Long Covid-19.
Not yet recruiting·IImmunityBio, Inc.·Phase 2·NCT07108036·20 enrolled
Characterization of the Immunometabolic Signature in Long COVID-19.
Completed·UUniversity Hospital, Angers·N/A·NCT05758480·62 enrolled
Use of Homeopathy in Patients Suffering From Long COVID-19
Completed·—·N/A·NCT06002230·15 enrolled
A Pilot Randomized Trial of rTMS for Fatigue and Brain Fog and Neuropsychiatric Symptoms of Long-COVID.
Completed·UUniversity of California, Los Angeles·Preclinical·NCT06586398·10 enrolled
Long COVID-19 Cutaneous Signatures: An ARPA Funded Research Project
Completed·CCND Life Sciences·N/A·NCT07005947·237 enrolled
Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cells in the Treatment of Long COVID-19
Withdrawn·SShanghai East Hospital·Phase 2·NCT05719012
Fluvoxamine to Augment Olfactory Recovery For Long COVID-19 Parosmia
Withdrawn·WWashington University School of Medicine·Phase 2·NCT05216614
The Role of Glutathione Deficiency and MSIDS Variables in Long COVID-19
Withdrawn·UUniversity of California, Irvine·Phase 1·NCT05371288
REVERSE-Long COVID-19 With Baricitinib Study
Withdrawn·VVanderbilt University Medical Center·Phase 3·NCT05858515
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)